Overall, these findings suggest that a RIPK3‐PP2A‐ERK signaling axis regulates DP thymocyte homeostasis and may provide a potential therapeutic target to improve thymic lymphoma therapies. The gene discussed is RIPK3; the disease is thymus lymphoma.